ArticleAIDS (London, England)2025
The impact of the COVID-19 and mpox outbreaks on behaviours associated with HCV infection among MSM: results from the prerandomisation phase of a clinical trial.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess whether the COVID-19 and mpox outbreaks affected hepatitis C virus (HCV) related behaviours among men who have sex with men (MSM) with a cleared HCV infection.
designLongitudinal analysis from the international ICECREAM trial (2021-2024).
methodsDuring the prerandomisation phase (i.e., without any intervention) individuals completed questionnaires on sexual and drug use behaviours and whether the COVID-19 (since start trial) or mpox (shortly after the mpox outbreak in 2022) outbreaks caused changes in these behaviours, all referring to the preceding 6 months. We used mixed-effects logistic regression to model changes in behaviours due to COVID-19 or mpox measures and mixed-effects linear regression to model the average HCV-MOSAIC risk score, as a proxy of HCV-associated risk behaviour, over calendar time.
results220 MSM ( n = 117 from the Netherlands, n = 103 from France) were included. Among 208 that completed the baseline questionnaire, 171 (82.2%) were MSM with HIV. The proportion of individuals reporting any impact of COVID-19 restrictions on risk behaviours, mainly lowering number of partners, decreased from 74.7% in September 2021 to 6.7% in September 2024 ( P < 0.001) and reporting any impact of mpox from 41.9% in November 2022 to 6.0% in September 2024 ( P = 0.001). The average HCV-MOSAIC risk score remained constant over time ( P = 0.59) and was consistently ≥2.0, indicating high reinfection susceptibility.
conclusionHCV-related behaviours decreased when COVID-19 and mpox measures were in place. However, individuals still engaged in behaviours associated with HCV, highlighting the importance of continued sexual health services and prevention efforts during such outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.